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The sellar and parasellar (SPS) region is a complex area rich in vital neurovascular structures and as such may be the location of
ﬁrst manifestation of a systemic malignancy. Metastases to this region are rare; breast cancer is the most common source among
those that metastasize to the SPS region. Ophthalmoplegia, headache, retroorbital or facial pain, diabetes insipidus, and visual
ﬁeld defects are the most commonlyreported symptoms. Lack of speciﬁc clinical and radiological features renders SPS metastases
diﬃcult to diﬀerentiate from the other frequently encountered lesions in this area, especially when there is no known history of a
primarydisease.Currentlyaccepted managementismultimodalitytherapythatincludesbiopsyand/orpalliativesurgicalresection,
radiation, and chemotherapy. Although no signiﬁcant survival beneﬁts have been shown by the surgical series, surgical resection
may improve quality of life. Here we review the relevant literature and present six illustrative cases from our own institution.
1.Introduction
Metastatic lesions comprise approximately 1% of the tumors
in the sellar/parasellar (SPS) area for which patients undergo
transsphenoidal surgery (TSS) [1, 2]; however, it has been
reported in autopsy series that the rate of metastasis to these
areas could be as high as 28% [3]. Breast and lung cancer
are the two most common types of malignant tumors that
metastasize to the SPS region, with respective rates of 40%
and 33% [4]. Metastases of prostate [5] ,r e n a lc e l l[ 6], gas-
trointestinal [7], thyroid [8, 9], and pancreatic cancers [10],
and lymphoma [11], leukemia [12], melanoma [13], and
plasmocytoma [14] have also been reported.
Despite the advancement in the imaging modalities, tu-
mors that have metastasized to the SPS areas may still be
diﬃcult to diﬀerentiate from pituitary adenoma on radio-
graphic studies [2, 14, 15]. Thickening of the pituitary stalk
andinvasionofthecavernoussinusmaybesuggestiveofsuch
lesions, but invasion of the cavernous sinus may commonly
occur with pituitary adenomas. This distinction is also clini-
cally challenging, although there are very few symptoms that
suggest a metastatic lesion.
Management options are multimodal and vary depend-
ing on whether a primary source is known or on the likely
diﬀerential diagnoses based on the clinical and radiological
ﬁndings. Multimodal options include radiation therapy,
chemotherapy, and/or surgery [16, 17], although the tumor
invasivenessrenderssurgicalresectionlimited.Althoughsur-
gicalseries havenot shown any survival beneﬁts,thepatient’s
quality of life may be improved [10, 14].
In this paper, we review the clinical, endocrine, and radi-
ological features of the metastatic SPS tumors with currently
accepted therapeutic options based on the pertinent litera-
ture.Inaddition,wereport sixcasesfromourinstitutionand
discuss their management with long-term clinical outcome.
2.Materialsand Methods
A systematic review of the literature was performed using
PubMed and the bibliographies of reviewed articles. The
medical records of six patients admitted to the University of
Utah Health Sciences Center between 2001 and 2011 were
reviewed retrospectively. Clinical presentation, radiographic
studies,treatment,histopathologicalconﬁrmation,outcome,
and prognosis were recorded (Table 1). The institutional
Review Board approval was granted for this retrospective
clinical paper.2 International Journal of Surgical Oncology
Table 1: Clinical, endocrine, and radiologicalfeatures of 6 patients with metastatic tumors of the sellar/parasellar region.
Patient Age Sex Presenting
symptoms
Symptom
duration Primary disease Metastatic
lesion Location Management Outcome
17 7 m Retroorbital pain
Left nerve III palsy 4 months Prostate cancer Prostate cancer
CS and sella
extending to
inferior orbital
ﬁssure and upper
clivus
Transsphenoidal
biopsy,
radiotherapy,
chemotherapy
Stable
neurological
ﬁndings at
two months
28 2 f
Hearing loss
Facial pain
Numbness in
cranial nerve V1,
V2
Several
weeks Breast cancer Breast cancer
Petrous apex
extending to
Meckel’s cave,
lateral CS, and
IAC
Transcranial
biopsy,
radiotherapy,
chemotherapy
N/A
3∗ 79 m Cranial nerve III
and VI palsies
Several
weeks Prostate cancer Melanoma
Bilateral CS, sella,
clivus, and
posterior nasal
cavity
Transsphenoidal
biopsy N/A
42 1 m Horner’s syndrome
Facial pain 1m o n t h
Osteosarcoma
Renal cell
cancer
Renal cell
cancer
CS extending to
sphenoid sinus,
pterygopalatine
fossa,and optic
canal
Radiation,
chemotherapy N/A
54 2 f Gait instability
Headache 1 month Unknown Lymphoma
Sellar/suprasellar
lesion with
bilateral CS,
medial sphenoid
wing, and clivus
involvement
Transsphenoidal
biopsy,
chemotherapy,
possible
radiotherapy
N/A
65 7 f
Decreased visual
acuity
Peripheral vision
defect
1 month Breast cancer Breast cancer
Greater sphenoid
wing extending
to the anterior
clinoidal process
with the optic
nerve encasement
Transcranial
decompression
of optic nerve
and the CS,
radiotherapy
with possible
chemotherapy
Stable
neurological
ﬁndings and
primary
disease at
one year
CS: cavernous sinus, IAC: internal acoustic canal, N/A: not available
∗Patient was previously presented in McCutcheon et al.
3.Results
3.1. Patient 1. A 77-year-old man with known prostate
cancer presented with a four-month history of left retro-
orbital pain followed by left eye ptosis. At presentation, he
had complete left third nerve palsy. His visual acuity was
intact in both eyes, with full visual ﬁelds to confrontation.
Brain magnetic resonance (MR) imaging (Figure 1)s h o w e d
aheterogeneouslyenhancing mass lesionthatmeasured 29 ×
17 × 29mm involving the sella, with invasion of the left
cavernous sinus and the upper clivus. The lesion extended
to the inferior orbital ﬁssure and was centered in the sella
turcica and the cavernous sinus. A biopsy was obtained
via a transnasal transsphenoidal approach. A diagnosis of
metastatic prostate carcinoma was made. He subsequently
underwent chemotherapy and focused radiation to the sellar
region and was noted to have stable neurological examina-
tion ﬁndings two months after surgery, with no change in his
ophthalmoplegia.
3.2. Patient 2. An 82-year-old woman with known history
of breast cancer presented with several weeks’ complaint of
progressive left-sided hearing loss as well as facial pain and
numbness in the ﬁrst and the second divisions of the trigem-
inal nerve, respectively. On neurological examination, left-
sided hearing loss and facial numbness along the V1 and V2
distributions were conﬁrmed. MR imaging showed evidence
of a heterogeneously enhancing mass in the left petrous apex
that extended to involve Meckel’s cave, the lateral cavernous
sinus, and the internal auditory canal (Figure 2). A left
frontotemporal craniotomy was performed for biopsy. The
histopathological evaluationwas consistent with a metastatic
adenocarcinoma of the breast. She was discharged home on
postoperative day three in stable condition for followup with
oncology.
3.3. Patient 3. A 79-year-old man with known history of
prostate cancer presented with several weeks’ history ofInternational Journal of Surgical Oncology 3
(a) (b)
Figure 1: Axial and coronal T1-weighted MR imaging of the brain with gadolinium enhancement showing a heterogeneously enhancing
mass involving the sella with invasion into the left cavernous sinus and the superior clivus.
(a) (b)
Figure 2: Axial and coronal T1-weighted MR imaging of the brain with gadolinium enhancement demonstrating a heterogeneously
enhancing left petrous apex mass with extension into the adjacent middle cranial fossa and cerebellar pontine angle.
progressively worsening double vision and eventual right
eyeptosis. Neurologicalexamination revealedcompletethird
and sixth nerve palsies on the right side. The visual ﬁelds
were full to confrontation in both eyes with intact visual
acuity. MR imaging disclosed an enhancing soft tissue mass
involving the clivus, pituitary fossa, cavernous sinus, and
posterior nasal cavity (Figure 3) that surrounded both inter-
nal carotid arteries in the cavernous sinuses. An endonasal
transsphenoidal approach to the sphenoid sinus was carried
out to obtain a biopsy of the lesion. A histopathological
diagnosis of metastatic melanoma was made, and evaluation
was undertaken by the oncology team. (This patient was
included in the cases described by McCutcheon et al. [13].)
3.4. Patient 4. A 21-year-old man with a remote history
of osteosarcoma and newly diagnosed metastatic renal cell
carcinoma had complaints of worsening vision and facial
pain. Because there was a discrepancy in the pupillary size
between his eyes, he underwent a computed tomography
(CT) scan of the head, followed by craniofacial MR imaging,
which revealed an enhancing mass in the right sphenoid
sinus with adjacent extension. On neurological examination,
he was noted to have complete hemifacial numbness and
Horner’s syndrome on the right side. MR imaging of the face
demonstrated a homogeneously contrast-enhancing lesion
centered within the right sphenoid sinus measuring 33 ×
20 × 27mm (Figure 4). The lesion extended into the carotid
canal, pterygopalatine fossa, and optic nerve canal with
destruction of the vidian canal and foramen rotundum on
the right. No optic nerve involvement was recorded in the
images. The patient was referred to the oncology service for
radiation and possible chemotherapy.4 International Journal of Surgical Oncology
(a) (b)
Figure 3: Axial and coronal T1-weighted MR imaging with gadolinium enhancement showing a homogenously enhancing soft tissue mass
involving the clivus, pituitary fossa,cavernous sinus, and posterior nasalcavity.
(a) (b)
Figure4:AxialandcoronalT1-weighted, gadolinium-enhancedMRimagingrevealingahomogenouslyenhancinglobulatedlesioncentered
within the right sphenoid sinus with extension into the carotid canal, pterygopalatine fossa,and optic nerve canal.
3.5. Patient 5. A 42-year-old woman with several weeks
of frontal headaches initially presumed to be secondary to
a sinus infection underwent MR imaging after antibiotic
medications failed to alleviate her symptoms. Her neuro-
logical examination was nonrevealing except for mild gait
instability. Brain MR imaging demonstrated a lobulated,
25 × 20-mm sellar and suprasellar lesion with extension
into the right cavernous sinus and encasement of the right
internal carotid artery. This lesion was isointense on T1- and
T2-weighted images and heterogeneously enhancing with
gadolinium administration. A CT scan was consistent with a
lyticlesion involving thecentralskull base extendinglaterally
and posteriorly to involve the bilateral medial sphenoid
wings and the clivus, respectively. A transnasal approach was
undertaken to obtain a biopsy of the lesion. Histopathologic
evaluation was consistent with a diagnosis of diﬀuse large B-
cell lymphoma (Figure 5).
3.6.Patient 6. A 53-year-old woman presented with aknown
diagnosis of breast cancer and a one-year history of wors-
ening left eye vision with a more precipitous decline in the
last month. MR imaging of the brain demonstrated a skull
base lesion involving the left sphenoid bone, the anterior
clinoidal process, and the cavernous sinus. On neurological
assessment, the patient was noted to have an acutely dimin-
ished visual acuity in her left eye to a level of ﬁnger counting
with left temporal visual ﬁeld cut. MR imaging (not shown)
showed a homogenously contrast-enhancing lesion of the
skullbaseinvolvingthegreatersphenoidwingandtheanteri-
or clinoidal process with encasement of the optic nerve onInternational Journal of Surgical Oncology 5
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Figure 5: Axial and coronal T1-weighted MR imaging of the brain with gadolinium enhancement demonstrating a heterogeneously
enhancing lobulated sellar and suprasellar lesion with extension into the right cavernous sinus and encasement of the right internal carotid
artery.
the left. A left frontotemporal craniotomy was performed for
biopsy of the lesion and to decompress the optic nerve and
the cavernous sinus with a subtotal resection. Histopatho-
logical analysis conﬁrmed the diagnosis of metastatic breast
carcinoma. The patient did not experience improvement
in her vision postoperatively. She underwent fractionated
radiotherapy to the involved area. One year after surgery,
her neurological ﬁndings were unchanged, and her systemic
disease was under control.
4.Discussion
4.1. Tumor Sites of Origin. Neoplasms originating from a
multitude of sites have been reported to metastasize to the
SPS region. Breast and lung cancer account for approxi-
mately two-thirds of SPS metastases, being the most com-
mon sources in women and men, respectively, [11, 18–21].
Histological examinations of the tissue samples obtained
during palliative hypophysectomy performed in patients
with end-stage breast cancer and from autopsy series have
documented metastasis to the SPS region in 6% to 29% of
cases [3, 22–25]. Breast cancer metastasis comprised 33% of
ourcasespresented inthisstudy. One hypothesisputforth to
explainthisprevalenceisthattheprolactin-richenvironment
of the pituitary enhances the proliferation of breast tumor
cells[10].Aftercarcinomaofbreastandlung,lymphomaand
prostate cancer have been reported to be the most common
sources of metastasis to SPS region [6]. Liver, renal cell,
colon, and thyroid cancers and melanoma are rare sources
of distant metastases to this region. The relatively rarer
occurrenceofourothercases, prostate,melanoma, renalcell,
and lymphoma, is consistent with the literature. Most cases
are found in the sixth or the seventh decade of life as a
part ofa generalizedmetastatic spread, commonlyassociated
with multiple, particularly osseous metastases [18, 20];
however, metastases can occur in young patients. The age
of presentation ranged from 21 to 82 years in our small
series, with an average age of 60 years. Very occasionally,
these lesions are the ﬁrst manifestation of an occultcancer or
t h eo n l ys i t eo fm e t a s t a s i s[ 14, 20]. Thus, ina patientwithout
any prior history of cancer, an SPS lesion cannot be assumed
to be an adenoma, just as in a patient with a known primary
cancer, it is not always metastatic. Clinically, metastasis is
generally suspected in patients with rapid onset and progres-
sive symptoms, irrespective of a history of malignancy.
4.2. Pathogenesis of Metastasis. T h ep o s s i b l em e t a s t a t i cp a t h -
ways to the pituitary and parasellar region include direct
blood-borne metastasis to the posterior pituitary lobe, pitu-
itary stalk, clivus, dorsum sellae, or cavernous sinus or lep-
tomeningealspreadwithinvolvementofthepituitarycapsule
[10, 26, 27]. There has been some controversy regarding the
most common location of metastasis within the pituitary
gland. Authorsof early series have reported that the majority
of pituitary metastasis occurs in the posterior pituitary, but
some dispute this claim. Teears and Silverman [4]r e p o r t e d
that 57% of the lesions localized to the posterior pituitary
alone, 13% to the anterior pituitary alone, 12% to both
lobes, and the remaining 18% to the capsule or stalk. They
hypothesized that the posterior pituitary, by receiving direct
arterial supply, is more likely to develop metastases than the
adenohypophysis, which receives its blood supply from the
hypophyseal portal system. The posterior lobe has a larger
area of contactwith theadjacent dura, which may beanother
contributing factor [4, 18]. Metastatic inoculation in the
anterior lobe is usually the result of contiguous spread from
the posterior lobe [28].
4.3. Clinical Presentation. Clinical symptomatology varies
dependingonthelocationofmetastaticinvolvement.Cranial
nerve palsies are the most frequent symptoms in cases of
cavernous sinus metastases. These may be isolated, such as6 International Journal of Surgical Oncology
diplopia or ptosis, with the third (oculomotor) and the
sixth (abducens) nerves being the most commonly involved,
followed by the fourth (trochlear) nerve [14, 29–31], or
they may appear in a constellation of symptoms charac-
terized by unilateral, rapidly progressive ophthalmoplegia
with retroorbital pain. This latter presentation is the usual
presentation of the cavernous sinus syndrome, also known
as parasellar syndrome [32]. If the branches of the trigem-
inal nerve are aﬀected, alteration in the facial sensation,
facial pain, or dysesthesia occurs [33]. Headache has been
reported as a rather common symptom, with an incidence
as high as 70% [14, 34, 35]; however, the majority of
pituitary metastases are clinically silent. In the autopsy study
by Teears and Silverman [4], only 7% of the pituitary
metastases were symptomatic. These metastases are often
seen in patients with terminal malignancy who present
with malaise, generalized pain, central nervous system
involvement, or treatment-associated symptoms, although
symptoms of pituitary insuﬃciency may be masked. Several
studies have indicated that diabetes insipidus (DI) was the
most common symptom [10, 20, 24, 36, 37]. In the series
of McCormick et al. [2], DI developed in 70% of patients;
however, if the anterior pituitary function is compromised,
DI may be concealed by reduced mineralocorticoid func-
tion [10]. Once the corticosteroid treatment is instituted,
DI becomes clinically evident. In some recent series, DI
has not been reported, which is likely because modern
imaging techniques are able to detect abnormalities earlier
than the timeframe required for DI development [35].
Other rarer hormonal ﬁndings may be hypothyroidism
and hypoadrenalism, hypogonadism, or overproduction of
adrenocorticotropic hormone (ACTH), growth hormone
(GH), or prolactin [10, 38–40].
Because of their invasiveness, pituitary metastatic lesions
have a high potential to cause visual deﬁcits from suprasellar
extension, with an incidence as high as 50% reported by
Branch Jr. and Laws Jr. [14]a n do t h e r s[ 10, 34, 41]. In both
the series by Chiang et al. [18] and that of Sioutos et al.
[20], bitemporal hemianopsia was the most common type of
visual impairment. Cranial nerve palsies involving the third
and the sixth nerves and facial pain with numbness (trigem-
inal origin) were the most common presentation (33%) in
our cases with cavernous sinus involvement. Retro-orbital
pain,visioncompromise,gaitinstability,Horner’ssyndrome,
and hearing loss were infrequent and associated with petro-
clival and sphenoorbital extension of the lesions. All these
symptoms were experienced with a relatively rapid onset
from a few weeks to a few months that suggested the aggres-
sive character of the lesions.
Symptoms strongly suggesting metastasis in the parasel-
lar or sellar space include painful ophthalmoplegia in associ-
ation with the sudden onset of DI [10, 26, 34, 42]. The pain
mayberetro-orbital or maybe duetotrigeminal dysfunction
[43–45] .I no u rs e r i e s ,5o ft h e6( 8 3 % )p a t i e n t sh a dap r e -
vious history of malignant disease. One of the patients
that had prior history developed a malignancy (melanoma)
other than the original one. Only one patient without a
prior history of malignancy ﬁrst presented with lymphoma
metastasis to the SPS region.
4.4. Imaging. Because pituitary adenomas also present with
invasion of the sellar ﬂoor, cavernous sinus, or clivus, no
speciﬁc neuroimaging criteria to deﬁne metastatic lesions
in SPS region have been reported. The diagnostic imaging
tools for SPS metastasis mainly include high-resolution CT
and MR imaging. Although CT is superior to MR imaging
in detecting the bone involvement, the latter is preferable to
determine the relationship of the lesion to the surrounding
neurovascular structures [46]. Although nonspeciﬁc, the
characteristics of these lesions on MR imaging are an iso-
or hypointense mass on T1-weighted imaging with a usually
hyperintense signal on T2-weighted imaging, and homoge-
neously enhancing mass in images obtained after the admin-
istration of contrast agent [47]. Invasion of the cavernous
sinus, sclerotic changes around the sella turcica and clivus,
isointense signal on both T1- and T2-weighted imaging,
and loss of high-intensity signal in the posterior pituitary
have been reported to be helpful in diﬀerentiating metastatic
lesions from benign ones [15, 30, 48]. Morita et al. [10]a n d
Komninos et al. [40] found that thickening or enhancement
of the infundibulum was the most characteristic CT or MR
imaging feature [15]. Schubiger and Halter [37]r e p o r t e d
that the invasion of the infundibular recess by a suprasellar
mass is suggestive of metastasis. Because of the rapid
growth of metastatic lesions, a dumbbell-shaped intra- and
suprasellar tumor with indentation at the diaphragm level
is generally indicative for these cases [20, 37, 49]. The
above-mentioned imaging characteristics are not speciﬁc for
sellar or parasellar metastases. The radiodiagnostic ﬁndings
that suggested a malignant/metastatic process in our cases
were the involvement of multiple compartments in the
anterior, middle, posterior cranial fossae, extension to the
infratemporal and pterygopalatine fossae, sphenoid sinus,
andnasalcavitywithbonydestructioninthecranialbaseand
asymmetric or bilateral invasion into the cavernous sinus.
4.5. Clinical Management. The management of SPS metas-
tases is multimodal, including surgical resection, radiation
therapy, and chemotherapy [50]. Treatment is mainly pallia-
tiveand dependsonthesymptoms andtheextentofsystemic
disease [10, 51]. Because of the invasiveness and the high
vascularity of the tumor, total surgical resection is generally
not undertaken [1, 20]. Therefore, surgical treatment should
aim for symptomatic relief and the preservation of visual
function, even in patients with widespread primary disease,
and should be followed by local radiation treatment and/or
chemotherapy [10, 51]. The body of evidence is inconclusive
on the eﬀect of the latter two modalities on survival [14, 52].
Morita et al. [10] and Branch Jr. and Laws Jr. [14]r e p o r t e d
improvement in symptoms, especially in pain and visual
ﬁeld defects, with no diﬀerence in survival after complete
resection compared with subtotal or partial resection [10,
14]. On the other hand, others have supported the concept
of improvement in survival after surgical resection of the
lesion [53–55]. Surgical exploration is also essential if tissue
diagnosis islikelytoaﬀecttherapyinpatientswithno known
primary malignancy. Resection is most commonly done
via transsphenoidal route, although subfrontal or pterional
approaches are also options depending on the location andInternational Journal of Surgical Oncology 7
the extension of the lesion. Four out of six patients in our
series underwent surgical biopsy through either transsphe-
noidal or transcranial route and then underwent subse-
quent radiation/chemotherapy. One patient who had visual
compromise had subtotal resection for palliation followed
by radiation/chemotherapy. One patient who had renal cell
carcinoma was directly referred to radiation oncology for
immediate radiation and subsequent chemotherapy.
Besides its role as an adjunct after surgery [14, 42, 56],
radiosurgery or conventional radiation is recommended as
the initial course of treatment in patients with systemic dis-
ease out of control, recurrence in the systemic disease with
concomitant SPS metastasis, or medical comorbidities that
put the patient at risk for a surgical intervention [2, 7,
18, 41, 57–62]. Conventional radiation therapy can achieve
symptom relief as high as 78% [62]. Radiosurgery, which
is considered less invasive than conventional radiation, has
been reported to achieve good tumor control [63, 64]. In a
series of 23 patients by Iwai et al. [17], the rates of tumor
control and symptom improvement were 67% and 53%,
respectively; however, radiosurgery to the SPS region is
limited by its potential to cause radiation injury to the
surrounding neurovascular structures such as optic appara-
tus, pituitary gland, or cranial nerves coursing in cavernous
sinus. Doses reported in the literature for these structures
range from 8 to 40 Gy [63, 65–68], and the optimal dose may
be quite variable depending on the proximity of the lesion.
Furthermore, the debate about whether the radiation should
be directed to the SPS region alone or to the entire brain
continues.
Chemotherapy is commonly used alone or along with
radiation therapy mostly for palliation in the treatment of
metastatic disease in SPS region [69]. Its value has not been
adequately studied and reported in the literature.
4.6. Prognosis. The prognosis of patients with metastases to
the SPS region is grim in a majority of cases because of the
aggressive character of the primary disease [58]. Even in
patients with no other metastasis at the initial evaluation,
the prognosis remains poor because of radiologically unde-
tectable microscopic metastases; however, it has been sug-
gested that the extent of systemic disease aﬀects survival
in these patients [14]. Patients with a single SPS region
metastasis may have a better outcome [10, 20]. Median
survival is less than 2 years independent of the management
strategy [10, 14, 70]. The records on the long-term follow-
up of the majority of our patients are lacking because the
patients were not monitored for surgical outcome, or the
follow-up periods were too short. The only patient that had
palliative surgery forvision compromise was seen at one year
after the surgery with stable neurological ﬁndings.
5.Conclusion
Sellar and parasellar metastatic lesions are relatively rare.
Breast and lung have been reported to be the most common
sources in both sexes. Suggestive symptoms include rapid
onset of progressive ophthalmoplegia with retro-orbital or
facial pain, visual impairment, and/or DI. Management va-
ries depending on whether a primary source is identiﬁed, the
symptomatology, the location and extent of the lesion, the
stage of the primary disease, and the medical comorbidities.
Subtotal or partial surgical resection is aimed mainly for
symptom relief. A multimodal approach involving subto-
tal resection of the lesion followed by radiation and/or
chemotherapy is widely accepted, especially in symptomatic
patients whose primary disease is under control. Radiation
with or without chemotherapy is generally recommended
as ﬁrst-line treatment in patients with advanced primary
disease or in those with high-risk medical comorbidities.
A biopsy usually precedes radiation therapy if the primary
source of the metastasis is unknown. The prognosis for
patients is generally poor, independent of the therapeutic
modality, and the overall survival is less than two years.
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